Trastuzumab: in HER2-positive metastatic gastric cancer.
about
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationComparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer.Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticlesAlterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.Reduced expression of ZDHHC2 is associated with lymph node metastasis and poor prognosis in gastric adenocarcinoma.Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal DiseaseOmics Screening for Pharmaceutical Efficacy and Safety in Clinical PracticeIdeal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.Biospecimens and biorepositories for the community pathologist.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesTrastuzumab: a review of its use in HER2-positive advanced gastric cancer.HER2 therapies and gastric cancer: a step forward.Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment.Gastric cancer management: Kinases as a target therapy.Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers.Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer.Trastuzumab in HER2-positive metastatic gastric cancer: profile report.
P2860
Q26765941-50AFCFE9-4BB9-449B-A649-3778C50B9267Q33799233-37743BA5-C5F6-44D5-BA64-FF381A0C0AAAQ34028831-0E65EECF-ECAC-4BE5-BF25-AE764A6882BAQ34498746-688FDF3F-FF96-4E8A-A8CD-9CA08C8E5CCFQ34606776-9402AD7B-6CBB-45C7-BEDA-F80D46847AAFQ35650273-91D722FA-2C8E-4DF7-B314-66A44CF1E50FQ36477760-DEECC683-A423-41F5-98CD-474FD23B1B97Q36546068-EC56D1BE-186E-44B2-9C66-E5898CD183BCQ36770491-9DF8D941-3BEA-4942-84FA-4A04A901D2D5Q36920645-05B850C7-6C21-4D7C-8138-EA296AB4863EQ37241496-C4946E54-3ED6-44C6-BD87-83D4412ABC88Q38140697-952F9E18-E51B-4808-B622-4EB14C5F21BEQ38151672-E3398EDB-1A22-4795-B0AA-A4A6F8B0C75EQ38212216-91B3A02A-5378-4270-BBDA-54A3428B5BDEQ38749038-0D2D9F6C-035B-49AB-8C97-2D7E879C6341Q39816033-4738EB8B-3B3A-4DF8-9473-3235203DB37AQ44978934-75EF0299-1E5F-408A-A6BA-C7706FA82354Q54569855-0C0A838F-B3C7-404C-9E48-EC0752298C06
P2860
Trastuzumab: in HER2-positive metastatic gastric cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trastuzumab: in HER2-positive metastatic gastric cancer.
@en
Trastuzumab: in HER2-positive metastatic gastric cancer.
@nl
type
label
Trastuzumab: in HER2-positive metastatic gastric cancer.
@en
Trastuzumab: in HER2-positive metastatic gastric cancer.
@nl
prefLabel
Trastuzumab: in HER2-positive metastatic gastric cancer.
@en
Trastuzumab: in HER2-positive metastatic gastric cancer.
@nl
P1433
P1476
Trastuzumab: in HER2-positive metastatic gastric cancer.
@en
P2093
Jamie D Croxtall
Kate McKeage
P304
P356
10.2165/11205900-000000000-00000
P577
2010-12-01T00:00:00Z
P6179
1000184351